Focusing on the forefront of medical progress and advocating the concept of translational research, the international forum on clinical and translational medicine was solemnly held at Shanghai University of Traditional Chinese Medicine from September 23 to 25, 2016. The forum is jointly sponsored by the Chinese Academy of Engineering, the Chinese Academy of Medical Sciences and the Clinical Research Center of US National Institutes of Health. Fan Daiming, the vice president of the Chinese Academy of Engineering, Cao Xuetao, the president of the Chinese Academy of Medical Sciences, John I.Gallin from the Clinical Research Center of US National Institutes of Health, and Ivana Knezevi, from Department of Basic Medicines and Medical Products of the World Health Organization, served as co-chairs of the conference. Sang Guowei, the former vice chairman of the National People's Congress and the chairman of the Chinese Institute of Medicine, gave keynote speeches for the forum. Dr. Lu Xianping, the president and chief scientific officer of CHIPSCREEN BIOSCIENCES, was invited to attend the forum.

In the sub-forum on " personalized drugs--targeted anti-tumor drugs", Dr. Lu Xianping gave a report on " selective histone deacetylase inhibitors in tumor immunotherapy and its future". He pointed out that China is expected to become the world's second largest pharmaceutical market after the United States in 2017. However, China's new drug research and development institutions are still developing generic drugs to a large extent, lacking original Chinese products and innovative drugs with brand appeal, especially small molecular drugs with global patents. CHIPSCREEN BIOSCIENCES focuses on the research and development of original small molecule drugs. With the self-created " integrated drug discovery and early evaluation platform based on chemical genetics" as its core competitiveness, it develops new drugs with better clinical efficacy and better safety in the fields of tumors, endocrine and autoimmune diseases. Chidamide is the first generation selective HDAC inhibitor developed by CHIPSCREEN BIOSCIENCES to treat peripheral T-cell lymphoma. In the future, its monotherapy and combined therapy with other drugs may bring new therapeutic methods to tumor patients.

The forum attracted more than 100 experts from more than 10 countries including China, the United States, Britain, Australia and other international organizations such as WHO, as well as more than 600 representatives from domestic and foreign scientific research institutes, hospitals, enterprises and relevant regulatory authorities. So far, the forum has successfully held five sessions, which have produced beneficial impetus to the development of clinical and translational medicine.

The purpose of the international clinical and translational medicine forum is to establish a bridge for international cooperation and exchange between clinical and translational medicine, to place on the agenda that the basic, clinical and translational research international cooperation that is of common concern to medical and health researchers and experts and scholars in interdisciplinary fields, and to carry out extensive and fruitful exchanges and cooperation.